| Company/Division name | ImmPACT Bio |
| Parent company | ImmPACT Bio |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2023 |
| Year reshoring implemented or to be implemented: | 2023 |
| City reshored to: | Los Angeles |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | end-to-end autologous CAR T-cell therapy prod. |
| What domestic positive factors made reshoring more attractive? | Better Control of Process/Delivery/Factory, Customization/Flexibility, Eco-system synergies, Higher productivity, Manufacturing/engineering joint innovation (R&D) |
